Building the Next Generation of Theranostics for Female Cancers
A focused pipeline designed around female biology, unmet needs, and precision delivery.
GAIASO’s pipeline is purpose‑built to address the cancers where women have been most underserved by current radiopharmaceutical and oncology approaches. Each program is designed end‑to‑end from target selection through to clinical application – informed by female biology, disease behaviour, and real‑world unmet need.
Our approach prioritises high‑impact female cancer indications, targets selected for both diagnostic and therapeutic relevance, and molecules engineered for precision, safety and scalability.
Women’s cancers remain highly lethal
Breast and gynaecological cancers account for the greatest cancer burden in women globally, yet outcomes remain disproportionately poor. Today’s clinical reality often includes:
- Late diagnosis and high rates of advanced disease
- Diffuse, microscopic tumour burden that is difficult to detect and eradicate
- Poor tumour mapping, limiting treatment precision
- Limited precision therapies, with off‑target toxicity and suboptimal efficacy
- Resistance, relapse and disease progression
Despite advances in oncology, therapy selection is still too often blind to tumour biology.
We need a new paradigm — one that sees, selects and treats what matters most.
Our Solution
Precision oncology with radiotheranostics. GAIASO applies a theranostic approach that matches the right patient to the right therapy. One platform. Three steps.
- See — Whole‑body disease mapping to visualise tumour burden in real time and help identify patients most likely to benefit.
- Select — Precision patient selection based on tumour biology using highly selective molecular imaging.
- Treat — Targeted radiotherapeutics that deliver radiation to cancer cells while sparing healthy tissue.
Radiotheranostics are targeted radioactive “keys” that find tumour “locks” — using one isotope to image disease and another to treat it. Our strategy supports expansion across programs by reusing core platform capabilities, helping us advance candidates efficiently as the portfolio grows.
GAIASO radiotheranostics are designed to integrate with standard chemotherapies, ADCs and biologics, immuno‑oncology agents, and maintenance and adjunct treatments. This flexibility supports combination strategies that can deliver deeper responses, longer remissions, and improved quality of life.
Target Indications
-
Breast cancer
-
Ovarian cancer
-
Endometrial cancers
-
Cervical cancer
-
and other cancers significantly impacted by female biology
Patients at the Centre
Her biology. Her voice. Her life. That’s our starting point.
Real Outcomes
Our model delivers what matters: earlier, more accurate diagnoses; fewer side effects; and treatments that acknowledge the urgency and reality of cancers affecting women.
Patient-First Model
Our number 1 priority is to get effective treatments to patients fast.
Want to get in touch?
Fill out our form and we'll get back to you shortly.
* Please note, all fields are mandatory
Prefer E-Mail? You can reach us directly at [email protected]
"*" indicates required fields